New horizons in fracture risk assessment

Age and Ageing

Volumn 42, Issue 5, 2013, Pages 548-554

  Aspray, Terry J ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fracture; Frax; Guideline; Osteoporosis; Qfracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; CLINICAL ASSESSMENT TOOL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE RISK ASSESSMENT; FRAGILITY FRACTURE; FRAX; GARVAN FRACTURE RISK ASSESSMENT TOOL; HEALTH ECONOMICS; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QFRACTURE; RISK ASSESSMENT; RISK FACTOR; VALIDATION STUDY;

FRACTURE; FRAX; GUIDELINE; OSTEOPOROSIS; QFRACTURE;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; DECISION SUPPORT TECHNIQUES; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84882733067     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/aft095     Document Type: Article

References (49)

1. Osteoporosis. National Institutes of Health Consensus Development Conference Statement. National Institutes of Health Consensus Development Conference Consensus Statement 1984; 5: 6. PubMed PMID: 6398406.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J 2001; 94: 569-73. PubMed PMID: 11440324.
3. Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1991; 1: 114-7. PubMed PMID: 1790392.
4. Davis SR, Kirby C, Weekes A, Lanzafame A, Piterman L. Simplifying screening for osteoporosis in Australian primary care: the Prospective Screening for Osteoporosis; Australian Primary Care Evaluation of Clinical Tests (PROSPECT) study. Menopause 2011; 18: 53-9. PubMed PMID: 20711081.
5. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001; 4: 373-80. PubMed PMID: 11748342.
6. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103: 3S-8S; discussion S-11S. PubMed PMID: 9302892.
7. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: WHO Study Group: Report: World Health Organization, 1994.
8. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265-9. PubMed PMID: 1973969.
9. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71. PubMed PMID: 2109197.
10. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9. PubMed PMID: 2113611.
11. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Min Res 1994; 9: 1137-41. PubMed PMID: 7976495.
12. Glucocorticoid-induced Osteoporosis: A Concise Guide to Prevention and Treatment. London: Royal College of Physicians, 2002.
13. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31: 331-52. PubMed PMID: 15123412.
14. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl. 1): S3-18. PubMed PMID: 18515009.
15. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-94. PubMed PMID: 15940371.
16. Yan L, Crabtree NJ, Reeve J et al. Does hip strength analysis explain the lower incidence of hip fracture in the People's Republic of China? Bone 2004; 34: 584-8. PubMed PMID: 15003807.
17. Arden NK, Baker J, Hogg C, Baan K, Spector TD. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res 1996; 11: 530-4. PubMed PMID: 8992884.
18. Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012; 23: 1191-8. PubMed PMID: 21901475.
19. Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-46. PubMed PMID: 17323110.
20. McCloskey E, Kanis JA. FRAX updates 2012. Curr Opin Rheumatol 2012; 24: 554-60. PubMed PMID: 22820516.
21. Rubin KH, Friis-Holmberg T, Hermann AP, Abrahamsen B, Brixen K. Risk assessment tools to identify women with increased risk of osteoporotic fracture. Complexity or simplicity? A systematic review. J Bone Miner Res 2013. PubMed PMID: 23592255. Apr 16. doi:10.1002/jbmr.1956 [Epub ahead of print].
22. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-97. PubMed PMID: 18292978. Pubmed Central PMCID: 2267485.
23. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012; 344: e3427. PubMed PMID: 22619194.
24. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335: 136. PubMed PMID: 17615182. Pubmed Central PMCID: 1925200.
25. Rabar S, Lau R, O'Flynn N, Li L, Barry P, Guideline Development G. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012; 345: e3698. PubMed PMID: 22875946.
26. Collins GS, Michaelsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported?. Curr Osteoporos Rep 2012; 10: 199-207. PubMed PMID: 22688862.
27. National Institute for HClinical E. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women (NICE technology appraisal guidance 160). London: National Institute for Health and Clinical Excellence, 2011.
28. National Institute for HClinical E. Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate And Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. (NICE technology appraisal guidance 161). London: National Institute for Health and Clinical Excellence, 2011.
29. National Institute for HClinical E. Osteoporotic Fractures - Denosumab (NICE technology appraisal guidance 204). London: National Institute for Health and Clinical Excellence, 2010.
30. Giangregorio LM, Leslie WD, Lix LM et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27: 301-8. PubMed PMID: 22052532.
31. National Osteoporosis Guideline Group on behalf of the Bone Research Society BGS, British Orthopaedic Association, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society & Society for Endocrinology. Osteoporosis. Clinical Guideline for Prevention and Treatment. Sheffield: University of Sheffield Press, 2008.
32. Osteoporosis: Fragility Fracture Risk: Osteoporosis: Assessing the Risk of Fragility Fracture. London: National Institute for Health and Clinical Excellence: Guidance, 2012.
33. Leslie WD, Morin S, Lix LM et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 2012; 23: 75-85. PubMed PMID: 21850546.
34. Bow CH, Tsang SW, Loong CH, Soong CS, Yeung SC, Kung AW. Bone mineral density enhances use of clinical risk factors in predicting ten-year risk of osteoporotic fractures in Chinese men: the Hong Kong Osteoporosis Study. Osteoporos Int 2011; 22: 2799-807. PubMed PMID: 21234548. Pubmed Central PMCID: 3186888.
35. Leslie WD, Lix LM, Johansson H et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Research 2010; 25: 2350-8. PubMed PMID: 20499367.
36. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009; 20: 1675-82. PubMed PMID: 19291344.
37. McCloskey EV, Johansson H, Oden A et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebocontrolled randomised study. Osteoporos Int 2009; 20: 811-7. PubMed PMID: 19002369.
38. Francis RM, Aspray TJ, Hide G, Sutcliffe AM, Wilkinson P. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008; 19: 895-903. PubMed PMID: 18071648.
39. McCloskey EV, Vasireddy S, Threlkeld J et al. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res 2008; 23: 1561-8. PubMed PMID: 18505372.
40. Leslie WD, Lix LM, Manitoba Bone Density P. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res 2011; 26: 460-7. PubMed PMID: 20839285.
41. Leslie WD, Lix LM, Wu X, Manitoba Bone Density P. Competing mortality and fracture risk assessment. Osteoporos Int 2013; 24: 681-8. PubMed PMID: 22736068.
42. Lekamwasam S, Adachi JD, Agnusdei D et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23: 2257-76. PubMed PMID: 22434203.
43. Hadji P, Hartenfels M, Kyvernitakis J, Hars O, Baumann KH, Kalder M. Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES). Breast Cancer Res Treat 2012; 133: 1089-96. PubMed PMID: 22453753.
44. Rizzoli R, Body JJ, De Censi A et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 2012; 23: 2567-76. PubMed PMID: 22270857.
45. Neubecker K, Adams-Huet B, Farukhi IM, Delapena RC, Gruntmanis U. Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos 2011; 2011: 924595. PubMed PMID: 21826255. Pubmed Central PMCID: 3150775.
46. Compston J, Bowring C, Cooper A et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75: 392-6.
47. Langsetmo L, Nguyen TV, Nguyen ND et al. Independent external validation of nomograms for predicting risk of lowtrauma fracture and hip fracture. CMAJ 2011; 183: E107-14. PubMed PMID: 21173069. Pubmed Central PMCID: 3033952.
48. Leslie WD, Majumdar SR, Lix LM et al. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 2012; 23: 391-7. PubMed PMID: 21365460.
49. Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CADargent-Molina P. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 2010; 25: 1002-9. PubMed PMID: 20200927. Pubmed Central PMCID: 3112173.